Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug614 | COVID-19 diagnostic test Wiki | 0.71 |
drug765 | Clinical Trial Matching Wiki | 0.71 |
drug3877 | modification of the planned therapeutic management Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D016889 | Endometrial Neoplasms NIH | 0.71 |
D004938 | Esophageal Neoplasms NIH | 0.71 |
D010051 | Ovarian Neoplasms NIH | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D013274 | Stomach Neoplasms NIH | 0.71 |
D014594 | Uterine Neoplasms NIH | 0.71 |
D014625 | Vaginal Neoplasms NIH | 0.71 |
D012878 | Skin Neoplasms NIH | 0.71 |
D009423 | Nervous System Neoplasms NIH | 0.71 |
D007680 | Kidney Neoplasms NIH | 0.71 |
D016543 | Central Nervous System Neoplasms NIH | 0.71 |
D014846 | Vulvar Neoplasms NIH | 0.71 |
D005909 | Glioblastoma NIH | 0.71 |
D008113 | Liver Neoplasms NIH | 0.71 |
D007822 | Laryngeal Neoplasms NIH | 0.71 |
D013736 | Testicular Neoplasms NIH | 0.71 |
D001943 | Breast Neoplasms NIH | 0.63 |
D002292 | Carcinoma, Renal Cell NIH | 0.50 |
D012004 | Rectal Neoplasms NIH | 0.50 |
D018281 | Cholangiocarcinoma NIH | 0.50 |
D018358 | Neuroendocrine Tumors NIH | 0.50 |
D010190 | Pancreatic Neoplasms NIH | 0.41 |
D006258 | Head and Neck Neoplasms NIH | 0.41 |
D002277 | Carcinoma NIH | 0.35 |
D003110 | Colonic Neoplasms NIH | 0.35 |
D008175 | Lung Neoplasms NIH | 0.29 |
D009369 | Neoplasms, NIH | 0.13 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0030079 | Cervix cancer HPO | 1.00 |
HP:0002896 | Neoplasm of the liver HPO | 0.71 |
HP:0008069 | Neoplasm of the skin HPO | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012114 | Endometrial carcinoma HPO | 0.71 |
HP:0100650 | Vaginal neoplasm HPO | 0.71 |
HP:0100006 | Neoplasm of the central nervous system HPO | 0.71 |
HP:0010788 | Testicular neoplasm HPO | 0.71 |
HP:0009726 | Renal neoplasm HPO | 0.71 |
HP:0012174 | Glioblastoma multiforme HPO | 0.71 |
HP:0030416 | Vulvar neoplasm HPO | 0.71 |
HP:0100615 | Ovarian neoplasm HPO | 0.71 |
HP:0010784 | Uterine neoplasm HPO | 0.71 |
HP:0100751 | Esophageal neoplasm HPO | 0.71 |
HP:0004375 | Neoplasm of the nervous system HPO | 0.71 |
HP:0006753 | Neoplasm of the stomach HPO | 0.71 |
HP:0100605 | Neoplasm of the larynx HPO | 0.71 |
HP:0003002 | Breast carcinoma HPO | 0.63 |
HP:0005584 | Renal cell carcinoma HPO | 0.50 |
HP:0100634 | Neuroendocrine neoplasm HPO | 0.50 |
HP:0100743 | Neoplasm of the rectum HPO | 0.50 |
HP:0030153 | Cholangiocarcinoma HPO | 0.50 |
HP:0002894 | Neoplasm of the pancreas HPO | 0.41 |
HP:0012288 | Neoplasm of head and neck HPO | 0.41 |
HP:0030731 | Carcinoma HPO | 0.35 |
HP:0003003 | Colon cancer HPO | 0.35 |
HP:0100526 | Neoplasm of the lung HPO | 0.29 |
HP:0002664 | Neoplasm HPO | 0.13 |
Navigate: Correlations HPO
There are 2 clinical trials
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Description: CTE Accrual
Measure: Proportion of patients Eligible for CTE versus Actual CTE Time: Through study completion, an average of 1 yearDescription: OS
Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: PFS
Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire
Measure: Identification of Barriers to CTE Time: Through study completion, an average of 1 yearDescription: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).
Measure: Real World Data Analytics Time: Through study completion, an average of 1 yearDescription: VTB Use Rate
Measure: Virtual Tumor Board Utilization Time: Through study completion, an average of 1 yearDescription: Time to CTE
Measure: Time from Intervention to Actual CTE (months) Time: Through study completion, an average of 1 yearThe current infection with the Coronavirus SARS-CoV-2 (COVID-19) is an exceptional health situation which requires an adaptation of our management practices in gynecological oncology. Data from the literature suggest that infection with Coronavirus is serious in subjects with cancer with a risk of severe form 5 times higher than that of the population without cancer and a risk of death multiplied by 8. In addition, the risk of infection would be 3 times greater in case of cancer. Faced with the COVID-19 epidemic, the investigator must organize themselves to ensure continuity in the treatment of patients with gynecological cancer but also adapt our practices in the management (CPR, teleconsultation, adaptation of treatment or even postponement of treatment). The objective of the High Council of Public Health is to be able to ensure adequate oncological care avoiding any potential loss of chance concerning the care of cancer: people affected must, despite the pandemic, have care allowing the same level of curability (localized cancers) or the same life expectancy (advanced cancers). This must be done by limiting as much as possible the impact on the organization of the service, the organization of patient follow-up and the psychological impact that these possible modifications could have. The hypotheses of our study are that the exceptional health situation linked to this pandemic leads to a change in the care of patients with gynecological cancer associated with a psychological impact and increased anxiety of patients during their care. Despite the extent of the pandemic, very little existing data makes it possible to define recommendations with a sufficient level of evidence.
Description: modification of the planned therapeutic management
Measure: percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy) Time: Day OAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports